Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy

British Journal of Ophthalmology

Volumn 97, Issue 5, 2013, Pages 617-621

  Hikichi, Taiichi ^a   Higuchi, Makoto ^a   Matsushita, Takuro ^a   Kosaka, Shoko ^a   Matsushita, Reiko ^a   Takami, Kimitaka ^a   Ohtsuka, Hideo ^a   Kitamei, Hirokuni ^a   Shioya, Shoko ^a  

^a Ohtsuka Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; JAPANESE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OCULAR BLOOD VESSEL; OUTCOME ASSESSMENT; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FOVEA; RETINAL THICKNESS; RETREATMENT; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; COLORING AGENTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; POLYPS; PROSPECTIVE STUDIES; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85027926990     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302652     Document Type: Article

References (26)

1. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10:1-8
2. Spaide RF,Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995.15. 100-10
3. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639-48
4. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010;55:501-15
5. Chan WM, Lam DS, Lai TYY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospec tive case series. Ophthalmology 2004;111:1576-84
6. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: compariso n of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008;92:1642-7
7. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002;22:529-35
8. Quaranta M, Maget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmo l 2002;134:277-80
9. Eandi CM, Ober MD, Freund KB, et al. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroida l neovascularization. Retina 2007;27:825-31
10. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculop athy in Japanese patients. Ophthalmology 2008;115:141-6
11. Wakabayashi T, Gomi F, Sawa M, et al. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008;92:936-40
12. Hikichi T, Ohtsuka H, Higuchi M, et al. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy. Retina 2011;31:857-65
13. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28:717-22
14. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146:513-19
15. Tsuchiya D, Yamamoto T, Kawasaki R, et al. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29:960-5
16. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011. 55. 39-44
17. Sayanagi K, Gomi F, Sawa M, et al. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2007;245:1569-71
18. Hikichi T, Higuchi M, Matsushita T, et al. One year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012;154:117-24
19. Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi 2005;109:417-27
20. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45:2399-406
21. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomographyguided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007. 143. 566-83
22. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J O phthalmol 2009;148:43-58
23. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee. Ranibizumab and bevacizumab for treatment of neovascular age-related macular deg eneration. Two-year results. Ophthalmology 2012;119:1388-98
24. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ra nibizumab clinical trials. Ophthalmology 2011;118:523-30
25. Wakabayashi T, Gomi F, Sawa M, et al. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vas culopathy. Br J Ophthalmol 2012;96:394-9
26. Iwama D, Hangai M, Ooto S, et al. Automated assessment of drusen using three-dimensional spectral-domain optical coherence tomography. Invest O phthalmol Vis Sci 2012;53:1576-83.